HPV16 E6-mediated stabilization of ErbB2 in neoplastic transformation of human cervical keratinocytes

Oncogene

Volumn 26, Issue 21, 2007, Pages 2988-2996

  Narisawa Saito, M ^a   Handa, K ^a   Yugawa, T ^a   Ohno, S ^a   Fujita, M ^a   Kiyono, T ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Cervical cancer; ErbB2; HPV16 E6; Primary human cervical keratinocytes

Indexed keywords

5 (2 BENZOTHIAZOLYL)THIOMETHYL 4 HYDROXY 3 METHOXYBENZYLIDENECYANOACETAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MUTANT PROTEIN; PROTEIN E6; PROTEIN P53; SHORT HAIRPIN RNA;

AGAR MEDIUM; ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CELL DENSITY; CELL IMMORTALIZATION; CELL STRAIN; CELL TRANSFORMATION; CONTROLLED STUDY; CULTURE MEDIUM; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; KERATINOCYTE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN STABILITY; PROTO ONCOGENE; REGULATORY MECHANISM; UPREGULATION; UTERINE CERVIX CARCINOMA; VIRUS CARCINOGENESIS;

CELL LINE, TRANSFORMED; CELL TRANSFORMATION, NEOPLASTIC; CELL TRANSFORMATION, VIRAL; CERVIX UTERI; FEMALE; HELA CELLS; HUMAN PAPILLOMAVIRUS 16; HUMANS; KERATINOCYTES; ONCOGENE PROTEINS, VIRAL; RECEPTOR, ERBB-2; REPRESSOR PROTEINS; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

PAPILLOMAVIRIDAE;

EID: 34248393855     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210118     Document Type: Article

References (32)

1. Al Moustafa AE, Foulkes WD, Benlimame N, Wong A, Yen L, Bergeron J et al. (2004). E6/E7 proteins of HPV type 16 and ErbB-2 cooperate to induce neoplastic transformation of primary normal oral epithelial cells. Oncogene 23: 350-358.
2. Beger M, Butz K, Denk C, Williams T, Hurst HC, Hoppe-Seyler F. (2001). Expression pattern of AP-2 transcription factors in cervical cancer cells and analysis of their influence on human papillomavirus oncogene transcription. J Mol Med 79: 314-320.
3. Bellone S, Palmieri M, Gokden M, Joshua J, Roman JJ, Pecorelli S et al. (2003). Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy. Gynecol Oncol 91: 231-240.
4. Gewin L, Myers H, Kiyono T, Galloway DA. (2004). Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. Genes Dev 18: 2269-2282.
5. Hudelist G, Czerwenka K, Singer C, Pischinger K, Kubista E, Manavi M. (2005). cDNA array analysis of cytobrush-collected normal and malignant cervical epithelial cells: a feasibility study. Cancer Genet Cytogenet 158: 35-42.
6. Hynes NE, Lane HA. (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354.
7. Kansra S, Stoll SW, Johnson JL, Elder JT. (2004). Autocrine extracellular signal-regulated kinase (ERK) activation in normal human keratinocytes: metalloproteinase-mediated release of amphiregulin triggers signaling from ErbB1 to ERK. Mol Biol Cell 15: 4299-4309.
8. Kelley ML, Keiger KE, Lee CJ, Huibregtse JM. (2005). The global transcriptional effects of the human papillomavirus E6 protein in cervical carcinoma cell lines are mediated by the E6AP ubiquitin ligase. J Virol 79: 3737-3747.
9. Kersemaekers AM, Fleuren GJ, Kenter GG, Van den Broek LJ, Uljee SM, Hermans J et al. (1999). Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res 5: 577-586.
10. Kihana T, Tsuda H, Teshima S, Nomoto K, Tsugane S, Sonoda T et al. (1994). Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix. Cancer 73: 148-153.
11. Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, Klingelhutz AJ. (1998). Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396: 84-88.
12. Kiyono T, Hiraiwa A, Ishii S, Takahashi T, Ishibashi M. (1994). Inhibition of p53-mediated transactivation by E6 of type 1, but not type 5, 8, or 47, human papillomavirus of cutaneous origin. J Virol 68: 4656-4661.
13. Kyo S, Nakamura M, Kiyono T, Maida Y, Kanaya T, Tanaka M et al. (2003). Successful immortalization of endometrial glandular cells with normal structural and functional characteristics. Am J Pathol 163: 2259-2269.
14. Ma YY, Wei SJ, Lin YC, Lung JC, Chang TC, Whang-Peng J et al. (2000). PIK3CA as an oncogene in cervical cancer. Oncogene 19: 2739-2744.
15. Nakano T, Oka K, Ishikawa A, Morita S. (1997). Correlation of cervical carcinoma c-erb B-2 oncogene with cell proliferation parameters in patients treated with radiation therapy for cervical carcinoma. Cancer 79: 513-520.
16. Ndubisi B, Sanz S, Lu L, Podczaski E, Benrubi G, Masood S. (1997). The prognostic value of HER-2/neu oncogene in cervical cancer. Ann Clin Lab Sci 27: 396-401.
17. Ngan HY, Cheung AN, Liu SS, Cheng DK, Ng TY, Wong LC. (2001). Abnormal expression of epidermal growth factor receptor and c-erbB2 in squamous cell carcinoma of the cervix: correlation with human papillomavirus and prognosis. Tumour Biol 22: 176-183.
18. Niibe Y, Nakano T, Ohno T, Suzuki Y, Oka K, Tsujii H. (2003). Prognostic significance of c-erbB-2/HER2 expression in advanced uterine cervical carcinoma with para-aortic lymph node metastasis treated with radiation therapy. Int J Gynecol Cancer 13: 849-855.
19. Pinion SB, Kennedy JH, Miller RW, MacLean AB. (1991). Oncogene expression in cervical intraepithelial neoplasia and invasive cancer of cervix. Lancet 337: 819-820.
20. Roskoski Jr R. (2004). The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 319: 1-11.
21. Rosty C, Couturier J, Vincent-Salomon A, Genin P, Freneaux P, Sigal-Zafrani B et al. (2004). Overexpression/amplification of HER-2/neu is uncommon in invasive carcinoma of the uterine cervix. Int J Gynecol Pathol 23: 13-17.
22. Sawada M, Kiyono T, Nakashima S, Shinoda J, Naganawa T, Hara S et al. (2004). Molecular mechanisms of TNF-alpha-induced ceramide formation in human glioma cells: P53-mediated oxidant stress-dependent and -independent pathways. Cell Death Differ 11: 997-1008.
23. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. (1993). The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75: 495-505.
24. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136.
25. Sharma A, Pratap M, Sawhney VM, Khan IU, Bhambhani S, Mitra AB. (1999). Frequent amplification of C-erbB2 (HER-2/Neu) oncogene in cervical carcinoma as detected by non-fluorescence in situ hybridization technique on paraffin sections. Oncology 56: 83-87.
26. Takeda Y, Mori T, Imabayashi H, Kiyono T, Gojo S, Miyoshi S et al. (2004). Can the life span of human marrow stromal cells be prolonged by bmi-1, E6, E7, and/or telomerase without affecting cardiomyogenic differentiation? J Gene Med 6: 833-845.
27. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al. (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19.
28. Woods Ignatoski KM, Dziubinski ML, Ammerman C, Ethier SP. (2005). Cooperative interactions of HER-2 and HPV-16 oncoproteins in the malignant transformation of human mammary epithelial cells. Neoplasia 7: 788-798.
29. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N et al. (1986). Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 319: 230-234.
30. Yang G, Cai KQ, Thompson-Lanza JA, Bast Jr RC, Liu J. (2004). Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem 279: 4339-4345.
31. Zimmermann H, Degenkolbe R, Bernard HU, O'Connor MJ. (1999). The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300. J Virol 73: 6209-6219.
32. zur Hausen H. (2002). Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350.